Refine your search
Collections
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Patil, Gayatri D.
- Review on Radiation Therapy on Cancer
Abstract Views :77 |
PDF Views:0
Authors
Affiliations
1 Ahinsa Institute of Pharmacy, Dondaicha 425408., IN
1 Ahinsa Institute of Pharmacy, Dondaicha 425408., IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 14, No 1 (2022), Pagination: 4-12Abstract
At high doses, radiation therapy kills cancer cells or slows their growth by damaging their DNA. Cancer cells whose DNA is damaged beyond repair stop dividing or die. When the damaged cells die, they are broken down and removed by the body.Radiation therapy does not kill cancer cells right away. It takes days or weeks of treatment before DNA is damaged enough for cancer cells to die. Then, cancer cells keep dying for weeks or months after radiation therapy ends. Radiation therapy is used to treat cancer and ease cancer symptoms. When used to treat cancer, radiation therapy can cure cancer, prevent it from returning, or stop or slow its growth.When treatments are used to ease symptoms, they are known as palliative treatments. External beam radiation may shrink tumors to treat pain and other problems caused by the tumor, such as trouble breathing or loss of bowel and bladder control. Pain from cancer that has spread to the bone can be treated with systemic radiation therapy drugs called radiopharmaceuticals.Keywords
Cancer therapy, Drug use.
References
- Ellis F. Dose, time and fractionation: a clinical hypothesis. Clin Radiol. 1969; 20:1–7. [PubMed] [Google Scholar]
- International Commission on Radiation Units. Prescribing, recording and reporting photon beam therapy. Supplement to ICRU Report 50. Bethesda: International Commission on Radiation Units and Measurement. MD: ICRU; 1999. [Google Scholar]
- Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, Eisbruch A. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early doseeffect relationships for the swallowing structures. Int J Radiat Oncol Phys. 2007; 68:1289–1298. [PubMed] [Google Scholar]
- Wang-Chesebro A, Xia P, Coleman J, Akazawa C, Roach M 3rd. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared to with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Phys. 2006; 66:654–662. [PubMed] [Google Scholar]
- Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, Roeske JC. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Phys. 2002; 52:1330–1337. [PubMed] [Google Scholar]
- Langen KM, Jones DT. Organ motion and its management. Int J Radiat Oncol Biol Phys. 2001; 50:265–278. [PubMed] [Google Scholar]
- Jaffray DA, Siewerdsen JH, Wong JW, Martinez AA. Flat-panel cone-beam computed tomography for image-guided radiation therapy. Int J Radiat Oncol Biol Phys. 2002; 53:1337–1349. [PubMed] [Google Scholar]
- Gill S, Thomas J, Fox C, Kron T, Rolfo A, Leahy M, Chander S, Williams S, Tai KH, Duchesne GM, Foroudi F. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol. 2011; 6:145. [PMC free article] [PubMed] [Google Scholar]
- Duma MN, Kampfer S, Wilkens JJ, Schuster T, Molls M, Geinitz H. Comparative analysis of an image-guided versus a non-imageguided setup approach in terms of delivered dose to the parotid glands in head-and-neck cancer IMRT. Int J Radiat Oncol Biol Phys. 2010; 77:1266–1273. [PubMed] [Google Scholar]
- Barney BM, Lee RJ, Handrahan D, Welsh KT, Cook JT, Sause WT. Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT) Int J Radiat Oncol Biol Phys. 2011;80:301–305. [PubMed] [Google Scholar]
- Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, Teh BS, McGarry RC, Cardenes HR, Timmerman RD. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010; 7:44–54. [PubMed] [Google Scholar]
- Tipton K, Launders JH, Inamdar R, Miyamoto C, Schoelles K. Stereotactic body radiation therapy: scope of the literature. Ann Intern Med. 2011; 154:737–745. [PubMed] [Google Scholar]
- Lo SS, Moffatt-Bruce SD, Dawson LA, Schwarz RE, Teh BS, Mayr NA, Lu JJ, Grecula JC, Olencki TE, Timmerman RD. The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol. 2011; 8:405–416. [PubMed] [Google Scholar]
- Wu QJ, Wang Z, Yin FF. The impact of respiratory motion and treatment technique on stereotactic body radiation therapy for liver cancer. Med Phys. 2008; 35:1440–1451. [PubMed] [Google Scholar]
- National radiotherapy implementation group report. Stereotactic body radiotherapy; Clinical review of the evidence for SBRT. UK: NRIG; 2010. [Google Scholar]
- Freeman DE, King CR. Stereotactic body radiotherapy for lowrisk prostate cancer: five-year outcomes. Radiat Oncol. 2011; 6:3. [PMC free article] [PubMed] [Google Scholar]
- Laramore GE. Role of particle radiotherapy in the management of head and neck cancer. Current Opin Oncol. 2009; 21:224–231. [PubMed] [Google Scholar]
- Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007; 25:953–964. [PubMed] [Google Scholar]
- Ma CM, Maughan RL. Within the next decade conventional cyclotrons for proton radiotherapy will become obsolete and replaced by far less expensive machines using compact laser systems for the acceleration of the protons. Med Phys. 2006; 33:571–573. [PubMed] [Google Scholar]
- Hall EJ. Cancer caused by x-rays-a random event? Lancet Oncol. 2007; 8:369–370. [PubMed] [Google Scholar]
- Baskar R. Emerging role of radiation induced bystander effects: Cell communications and carcinogenesis. Genome Integr. 2010; 1:13. [PMC free article] [PubMed] [Google Scholar]
- Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21:109–122. [PubMed] [Google Scholar]
- Verheij M. Clinical biomarkers and imaging for radiotherapyinduced cell death. Cancer Metastasis Rev. 2008; 27:471–480. [PubMed] [Google Scholar]
- Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys. 1995; 33:781–796. [PubMed] [Google Scholar]
- Rupnow BA, Knox SJ. The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis. 1999; 4:115–143. [PubMed] [Google Scholar]
- Cragg MS, Harris C, Strasser A, Scott CL. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer. 2009; 9:321–326. [PubMed] [Google Scholar]
- . Jager, P.L.; Que, T.H.; Vaalburg, W.; et al. Carbon-11 choline or FDG-PET for staging of oesophageal cancer? Eur. J. Nucl. Med. 28:1845–9; 2001.
- Ishiwata, K.; Kasahara, C.; Hatano, K.; et al. Carbon-11 labeled ethionine and propionine as tumor detecting agents. Ann. Nucl. Med. 1:115–22; 1997.
- Iozzo, P.; Osman, S.; Glaser, M.; et al. In vivo imaging of insulin receptors by PET: Preclinical evaluation of iodine-125 and iodine124 labelled human insulin. Nucl. Med. Biol. 29:73–82; 2002.
- Herlin, G.; Persson, B.; Bergstrèom, M.; et al. 11C-harmine as a potential PET tracer for ductal pancreas cancer: In vitro studies. Eur Radiol. 13:729–3; 2003.
- Brown, W.D.; Oakes, T.R.; DeJesus, O.T.; et al. Fluorine-18- fluoro-L-DOPA dosimetry with carbidopa pretreatment. J. Nucl. Med. 39:1884–91; 1998.
- Blankenberg, F.G.; Strauss, H.W. Nuclear medicine applications in molecular imaging. J. Magn. Res. Imaging 16:352–61; 2002.
- Oyama, N.; Akino, H.; Kanamaru, H.; et al. 11C-acetate PET imaging of prostate cancer. J. Nucl. Med. 43:181–6; 2002.
- Kotzerke, J.; Volkmer, B.G.; Glatting, G.; et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42:25–30; 2003.
- 38. Mathews, D.; Oz, O.K. PET in prostate and renal cell carcinoma. Curr. Opin. Urol. 12:381–5; 2002.
- DeGrado, T.R.; Baldwin, S.W.; Wang, S.; et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J. Nucl. Med. 42:1805–14; 2001
- Hara, T.; Kosaka, N.; Kishi, H. Development of (18)Ffluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J. Nucl. Med. 43:187– 99; 2002.
- Hara, T.; Kosaka, N.; Kishi, H. PET imaging of prostate cancer using carbon-11-choline. J. Nucl. Med. 39:990–5; 1998.
- Sutinen, E.; Nurmi M.; Roivainen A.; et al. Kinetics of [(11)C]choline uptake in prostate cancer: A PET study. Eur. J. Nucl. Med. Mol. Imaging 31:317–24; 2004.
- Chen, X.; Park, R.; Hou, Y.; et al. MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA- [Lys3] bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med. 45:1390–7; 2004.
- Rasey, J.S.; Koh, W.J.; Evans, M.L.; et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F] fluoromisonidazole: A pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 36:417–28; 1996.
- O’Donoghue, J.A.; Zanzonico, P.; Pugachev, A.; et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu (II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int. J. Radiat. Oncol. Biol. Phys. 61:1493–502; 2005.
- Piert, M.; Machulla, H.J.; Picchio, M.; et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J. Nucl. Med. 46:106–13; 2005.
- Chao, K.S.; Mutic, S.; Gerber, R.L.; et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensitymodulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 49:1171–82; 2001.
- de Jong I.J.; Pruim, J.; Elsinga, P.H.; et al. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur. Urol. 44:327–8; discussion 38–9; 2003.
- Ling, C.C.; Humm, J.; Larson, S.; et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int. J. Radiat. Oncol. Biol. Phys. 47:551–60; 2000.
- 50. Brahme, A. Individualizing cancer treatment: Biological optimization models in treatment planning and delivery. Int. J. Radiat. Oncol. Biol. Phys. 49:327–37; 2001.
- Xing, L.; Cotrutz, C.; Hunjan, S.; et al. Inverse planning for functional image-guided IMRT. Phys. Med. Biol. 47:3567–78; 2002. 52. Alber, M.; Paulsen, F.; Eschman, S.M.; et al. On biologically conformal boost dose optimization. Phys. Med. Biol. 48: N31–5; 2003.
- Yang, Y.; Xing, L. Towards biologically conformal radiation therapy (BCRT): Selective IMRT dose escalation under the guidance of spatial biology distribution. Med. Phys. 32:1473–84; 2005.
- Seppenwoolde, Y.; Shirato, H.; Kitamura, K.; et al. Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 53:822; 2002.
- Shirato, H.; Seppenwoolde, Y.; Kitamura, K.; et al. Intrafractional tumor motion: Lung and liver. Semin. Radiat. Oncol. 14: 10–8; 2004.
- Shimizu, S.; Shirato, H.; Ogura, S.; et al. Detection of lung tumor movement in real-time tumor-tracking radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 51:304–10; 2001.
- Xu, Q.; Hamilton, R. Novel respiratory gating method based on automated analysis of ultrasonic diaphragm motion. Med. Phys. 32:2124; 2005.
- Huang, M.H.; Lin, Y.S.; Lee, C.L.; et al. Use of ultrasound to increase effectiveness of isokinetic exercise for knee osteoarthritis. Arch. Phys. Med. Rehabil. 86:1545–51; 2005.
- Seiler, P.G.; Blattmann, H.; Kirsch S.; et al. A novel tracking technique for the continuous precise measurement of tumour positions in conformal radiotherapy. Phys. Med. Biol. 45: N103– 10; 2000.
- Review on Curcuma aromatic as an Herbal medicine
Abstract Views :79 |
PDF Views:0
Authors
Affiliations
1 Ahinsa Institute of Pharmacy, Dondaicha, Shindkheda, Dhule (MH)-425408, IN
1 Ahinsa Institute of Pharmacy, Dondaicha, Shindkheda, Dhule (MH)-425408, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 14, No 2 (2022), Pagination: 89-92Abstract
Curcuma aromatica is also a familiar Chinese herb used for treating diseases with blood stasis and has been consider as an effective anticancer herb. The rhizomes of Curcuma aromatic are used in original medicine for exterior applications on skin diseases, sprain, bruise, in snake poison, holdup the ageing process, pain relief, protecting against liver diseases and also to enhance complexion. The constituents identified in the oil is alphapinene, beta-pinene, camphene, 1,8-cineol, isofurano-germacrene, borneol, isoborneol, beta-curcumene, arcurcumene, xanthorrhizol, germacrone, camphor, and curzerenone and the constituent in oil was found to differ from place to place. Bioactive compounds, counting 1, 8-cineole, ar-curcumene, ar-turmerone, β-elemene, camphor, curcumol, curdione, germacrone, linalool, xanthorrhizol, and zingiberene, from the essential oil of C. aromatica have been verified to possess anticancer properties. Usually used as an anti- inflammatory agent. It possesses a wide range of activities like Anti –inflammatory, anti-tumor, immunological effects, wound healing, anti -fungal, anti -oxidant, anti - microbial, anti-diabetic, anti-platelet and mosquito repellent activity of wild turmeric. The use of analgesic drugs, such as opiates and NSAIDs, for pain relief has been stagnated as these drugs are reported to have adverse side effects, including addiction and gastrointestinal disorders.Keywords
Curcuma aromatica, Anti-diabetic, Analgesic drug, Wild turmeric.References
- Shamim A, Ali Mohammed, Ansari SH, Ahmed F. Phytoconstituents from the rhizomes of Curcuma aromatic Salisb. Journal of Saudi Chemical Society2011; 15:287-290.
- Pant N, Misra H, Jain DC. Phytochemical investigation ofethyl acetate extract from Curcuma aromatic Salisbrhizomes. Arabian Journal of Chemistry 2013; 6:279-283.
- Vasavda K, Hedge PL, Harini A. Pharmacological Activities of Turmeric (Curcuma longa linn): A Review. J HomeopAyur Med 2013; 2(4):133.
- Quality standards of Indian medicinal plants. Edn 1, Vol. 6, Indian Council of medical Research, Ramalinga swami Bhawan, 2008, 102- 109.
- Kojima H, Yanai T, Toyota A. Essential oil constituentsfrom Japanese and Indian Curcuma aromatica rhizomes. Planta Med 1998; 64(4):380-1
- Revathy S, Malathy NS, Antibacterial activity of rhizome of Curcuma aromatica and partial purification of active compounds. Indian Journal of pharmaceutical Sciences 2013; 75(6):732-735.
- Kumar A, Chomwal R, Kumar P, Renu S. Anti-inflammatory and wound healing activity of Curcuma aromatica salisb extract and its formulation. Journal of Chemical and Pharmaceutical Research 2009; 1(1):304-310